Table 5

Changes in HCT and Hgb levels

Longitudinal studies
Author (year)
Participants (N)Measure
(units)
Baseline
mean±SD
(95% CI)
Follow-up
mean±SD
(95% CI)
Number of months% ChangePT (nmol/L)
Base-post GAHT
TW
Wierckx (2014)40 (oral oestrogen)
12 (transdermal oestrogen)
HCT (%)45±2.5
45.5±1.7
42±5.7
42.2±2.3
12
12
−7.0
−4.6
<0.01
<0.001
18.0–0.4
19.7–0.5
Auer et al (2016)4620HCT (%)45.2±2.742.7±1.812−5.5<0.0117.5–1.9
Jarin et al (2017)3913HCT (%)43.842.36−3.4>0.0513.6–6.9
Vita et al (2018)4821HCT (%)44.8±2.940.1±2.66–30−10.5<0.00120.5–1.1
Defreyne et al (2018)19239HCT (%)45.0±2.5
(44.9–45.5)
41.0±3.1
(40.9– 41.7) 41.1±3.2
(40.5– 41.2)
40.7±3.2
(40.0– 40.8)
3
6
24
−8.9
−8.7
−9.6
<0.001
<0.001
<0.001
17.4–0.7
17.4–0.6
17.4–0.6
Tack et al (2017)4721HCT (%)43.8±1.939.9±2.212–31−8.9<0.00115.2–8.8
Gooren and Bunck (2004)4319Hgb (mmol/L)9.3±0.78.0±0.7
8.1±0.6
12
36
−14.0
−12.9
<0.001
<0.001
21.5–1.0
21.5–0.9
Olson-Kennedy et al (2018)4923Hgb (g/dL)153±11140±1212−8.3<0.00114.8–5.9
Wiik (2020)169
10
Hgb (g/L)148.3±10.1
150.3±9.1
132.7±9.1
133.3±9.0
4
12
−10.5
−11.7
<0.001
<0.001
18.0–0.5
18.0–0.5
Cross-sectional studies
Author (year)
Participants (N)Measure
(units)
TW
mean±SD or (range)
Control
mean±SD or (range)
Number of
months
% DifferencePT (nmol/L)
TW
TWCMCWHNTW
Lapauw et al (2008)542346HCT (%)41.2±2.345.3±2.3>48−9.1<0.0011.1
SoRelle et al (2019)5210573HCT (%)(35.9– 48.7)(39.0– 50.6)>6d=1.01.9
Greene et al (2019)1893HCT (%)(35–47)(35.5– 46)
CW
>12>0.051.4
Roberts et al (2014)53552020HCT (%)(34.6–43.7)(38.4– 45.7)
CM
(34.4– 41.9)
CW
>6
<0.01
>0.05
Jain (2019)182 (oestrogen)
95 (oestrogen
+progesterone)
92HCT (%)42.5
40.9
45.9±2.0>3−7.4
−10.9
<0.05
<0.05
Sharula (2012)3712922HCT (%)40.2±3.144.4±2.4>3−9.5<0.0012.5
  • CM, cismen; CW, ciswomen; HCT, haematocrit; Hgb, haemoglobin; HNTW, hormone-naive transwomen; TW, transwomen.